MolecularMD develops and commercializes specialty diagnostics for oncology applications. Tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD integrates proven and innovative platform technologies with clinical assay design, validation, and centralized testing to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. MolecularMD’s core competency is in streamlining the development, regulatory approval, and clinical deployment of precision oncology medicines. The company provides customized Clinical Trial Assay and CDx development in their CAP-accredited, CLIA-certified laboratories in Portland, Oregon and Cambridge, Massachusetts.